Parkinson’s Disease
CereGate (FOG LIGHTS)
The FOG LIGHTS study seeks to understand whether CereGate Therapy, an investigational therapy, may help reduce symptoms relating to freezing of gate in people with Parkinson’s Disease previously implanted with a Deep Brain Stimulation (DBS) system. This study offers enrollment to individuals who have been diagnosed with Parkinson’s Disease, have had DBS with a Boston Scientific Implant, and have freezing of gate.
The study involves 4 to 5 visits over about 3-4 months, and we expect each to take around 2 to 4 hours. At study visits participants may complete neurological examinations, walking tests, questionnaires, blood pressure measurements, and receive adjustments for their CereGate DBS program. Study personnel may ask that participants briefly stop taking Parkinsonian medications prior to certain study visits. In between study visits participants are asked to maintain a diary documenting symptoms relating to freezing of gate and have weekly check-ins via phone calls with research staff.
Contact: Sarah Simon
Email: ssimon3@uw.edu
Vercise DBS Registry
Vercise is a prospective clinical intervention study that seeks to understand the implementation of a new software tool in Parkinson’s Patients who have had Deep Brain Stimulation (DBS) with a Boston Scientific Implant. The study will document characteristics of real-world outcomes for Boston Scientific Corportation’s commercially approved Vercise System for DBS, when used according to the applicable instructions for use.
Participants who meet eligibility may complete neurological examinations, questionnaires, and receive adjustments for their Vercise DBS program.
Contact: Bianca Le
Email: bia7@uw.edu
BIAL
BIAL is a clinical trial that aims to evaluate the use of an experimental drug, BIA 28-6156, in subjects diagnosed with Parkinson’s Disease (PD) who have a specific genetic variant. The primary goal of this study is to assess the efficacy of BIA 28-6156 in delaying clinical motor progression in subjects with Parkinson’s Disease. Potential participants will undergo genetic testing to identify individuals with a specific genetic variant.
Participants who meet eligibility and genetic requirements will be randomized into 3 groups; 2 of the groups will receive a dosage of BIA 28-6156 and 1 group will receive a placebo, an inactive drug with no dosage. Participation will occur for up to a year and a half and involves clinic visits, movement and cognitive assessments, phone check-ins, daily oral medication, MRI scans, biological sample collection, and questionnaires.
Contact: Amy Good & Bianca Le
Email: amygood@uw.edu & bia7@uw.edu
Parkinson’s Disease (PD) Registry
The purpose of this research study is to build a registry or database of patients diagnosed with Parkinson’s Disease (PD). The database will include information about each participant’s disease and their contact information. By creating this database, we hope to make it easier for interested subjects to connect with researchers to enroll in studies specifically related to Parkinson’s. Research could include various clinical trials and interventions pertaining to treatment, prevention, and symptom management.
The study visit will be completed over the phone, on the computer, or in-person. At this visit study personnel may collect demographic information, medical history, and information related to your mood and cognition. When there is a study that a participant might be interested in, study staff will contact the participant by email or phone.
Contact: Bianca Le
Email: bia7@uw.edu